The United States is not facing an unsolved problem. Every other wealthy nation on earth has achieved universal healthcare coverage. They did it through different mechanisms, at different times, with different political circumstances — but they all got there. The question this piece examines is not whether universal coverage is achievable. It is what the international evidence shows about how it works, why some systems perform better than others, and what the US can learn from both the successes and the failures.
Four Models, One Outcome
Part 1 of this series introduced the four international frameworks through which countries have achieved universal coverage. This piece examines specific countries through those frameworks, with attention to what made each system work, where problems have emerged, and what the research identifies as the determining factors in system performance.
The four models — the Beveridge single-payer model, the Bismarck regulated nonprofit model, the mandated private insurance model, and the mixed public-private model — produce different structures but the same foundational outcome: every resident has access to healthcare regardless of their ability to pay. No wealthy country that has achieved this outcome has abandoned it.
Taiwan: The Gold Standard
Taiwan launched its National Health Insurance system in 1995. At that point, roughly 40% of the population was uninsured. The government set a goal of universal coverage and designed a single-payer system funded through income-based premiums and government contributions. Within one year, coverage reached 92% of the population. Today it covers 99.9% of Taiwanese residents.
Taiwan’s NHI has ranked first in the global Health Care Index for seven consecutive years. Its administrative overhead — the share of total program expenditures consumed by administration rather than patient care — is 1.07%. For context, administrative costs in the US healthcare system consume between a quarter and a third of all healthcare spending.
What made Taiwan work? Researchers point to three factors that distinguished Taiwan’s transition from those that have struggled. First, strong political leadership with sufficient legislative majority to enact and sustain the system. Second, a deliberate design process that studied other countries’ systems — particularly Canada and the US — before building Taiwan’s own. Third, and most significant for the American comparison: the absence of a powerful insurance industry lobby at the moment of implementation. Taiwan’s private insurance market was not large enough in 1995 to mount effective resistance to reform. The window for reform closed as that industry grew. This is not an incidental observation. It is the central structural lesson of Taiwan’s success for American policymakers.
Taiwan’s system is not without challenges. Provider payment rates have been a recurring source of tension, with some physicians arguing that fee schedules are too low. Pharmaceutical coverage decisions have generated debate. These are the ongoing management challenges of any large healthcare system. They have not undermined the system’s fundamental performance or its public support.
Model: Beveridge single-payer. Automatic enrollment. Government as single payer to private providers.
Germany: Universal Without Eliminating Private Insurance
Germany’s healthcare system is the oldest social health insurance system in the world, established in 1883 under Otto von Bismarck. It has achieved universal coverage through a network of nonprofit sickness funds — approximately 100 today — that are required by law to accept all applicants, cover a defined comprehensive benefit package, and charge income-based premiums rather than risk-rated premiums. Employers and employees share the premium cost. The government subsidizes participation for those with low or no income.
The Commonwealth Fund and OECD data consistently rank Germany highly on access, quality, and efficiency. Wait times are short. Patient choice of provider is broad. Public satisfaction is high. Per-capita spending is substantially lower than the US despite a more generous benefit package.
Germany’s system is particularly relevant for American discussions because it preserves a role for private insurance — approximately 11% of the population holds private insurance as an alternative to the sickness funds — while achieving universal coverage for the rest. The private insurance market is tightly regulated: premiums may not be based on health status, coverage must meet minimum standards, and individuals cannot simply opt out of contributing to the social system. This structure demonstrates that universal coverage does not require the complete elimination of private insurance; it requires that private insurance operate within a framework designed around universal access rather than around profit maximization.
Germany controls costs primarily through government negotiation of provider fee schedules and pharmaceutical prices. The prices Americans pay for drugs and procedures are not natural market outcomes — they are the result of the US government’s decision not to negotiate, while every other government does. Germany’s lower prices are the direct product of that negotiating power.
Model: Bismarck. Mandatory nonprofit sickness funds. Employer-employee contributions. Government price regulation.
Australia: Top-Ranked by the Commonwealth Fund
Australia’s Medicare system provides universal coverage to all Australian citizens and permanent residents through a combination of public funding and private supplementation. The public system covers hospital care and a significant portion of physician fees. Private insurance, held by approximately 44% of the population, covers additional services, private hospital rooms, and faster access to elective procedures.
The Commonwealth Fund’s 2024 Mirror Mirror report ranked Australia first overall among eleven high-income nations. Australia scored particularly well on equity — the degree to which outcomes and access are consistent across income levels — and on efficiency, including administrative simplicity.
Australia spends approximately $6,931 per person on healthcare annually, compared to $13,432 in the United States. It achieves this at roughly half the American cost while ranking first in overall performance and producing significantly better health outcomes on population-level measures.
The Australian system is funded primarily through general taxation and a dedicated Medicare levy — a 2% surcharge on taxable income. High-income earners who do not hold private insurance pay an additional surcharge, creating a financial incentive for private insurance participation that reduces pressure on the public system without making private insurance compulsory.
Model: Mixed public-private. Universal public baseline with regulated private supplementation.
France: Strong Outcomes, Short Waits
France achieves universal coverage through a mandatory social insurance system with multiple funds organized by occupation. Coverage is comprehensive — hospital care, physician visits, mental health, dental, vision, and pharmaceuticals — with cost-sharing that is partially reimbursed through supplementary insurance held by approximately 95% of the population.
France consistently ranks highly on physician supply, access to specialists, and health outcomes. Wait times for specialist care are substantially shorter than in Canada or the UK. Life expectancy and infant mortality outcomes are significantly better than the US. Per-capita spending is approximately half the American figure.
France’s system is notable for its approach to chronic disease management. Patients with serious chronic conditions receive full coverage with no cost-sharing — a deliberate policy choice to eliminate financial barriers to ongoing care for the conditions most likely to generate expensive acute episodes if undertreated.
Model: Bismarck variant. Mandatory social insurance funds. Government price-setting for all services.
Japan: Best Outcomes at Lowest Cost
Japan has achieved universal coverage through a combination of employment-based and residence-based insurance systems, covering all citizens and legally resident non-citizens. The system is notable for two reasons: Japan has among the best health outcomes in the developed world, and it achieves them at the lowest per-capita cost of any comparable wealthy country.
Japanese life expectancy is among the highest globally. Infant mortality is among the lowest. The system emphasizes preventive care and chronic disease management. Cost-sharing exists but is capped, and low-income individuals receive additional subsidies.
Japan’s drug and procedure prices are regulated by the government and set substantially below American prices. The price differential for pharmaceuticals — documented extensively in RAND Corporation research — is a direct result of government negotiating power vs. the US system’s prohibition on such negotiation.
Model: Bismarck. Employment-based and residence-based insurance covering all residents.
Canada: An Honest Assessment
Canada is the international comparison most frequently cited in American healthcare debates, and it deserves an honest treatment that neither dismisses its problems nor overstates them.
Canada’s provincial single-payer systems cover all citizens for hospital care and physician services. Wait times for specialist referrals and elective procedures are the system’s most documented weakness. The average wait from GP referral to specialist treatment is 21.2 weeks. For some procedures the waits are substantially longer. These figures are real, documented, and represent a genuine quality-of-access problem.
The causes of Canada’s wait time problem are equally well-documented. Canada ranks 27th out of 30 OECD countries in physician supply and 25th in hospital beds. The system was built with a financing structure for universal coverage but without the provider capacity to deliver it promptly. That is a political and planning failure, not a payment-model failure.
Canada’s health outcomes, despite its access problems, are substantially better than the US on most population-level measures. Life expectancy is higher. Infant mortality is lower. Mortality amenable to healthcare is lower. Canada spends significantly less per capita than the US and produces better outcomes while also having the wait time problem the US uses as its primary cautionary tale.
The lesson Canada offers is specific: universal coverage requires adequate provider capacity as well as adequate financing. A single-payer system that covers everyone but does not train enough physicians and build enough hospitals will have wait times. The solution is to train more physicians and build more hospitals — exactly what Canada has been working to address. It is not to abandon the coverage architecture.
Model: Beveridge. Provincial single-payer. Federal standards. Tax-funded.
The United Kingdom: What Happens When You Starve a System
The National Health Service was established in 1948 and for decades served as one of the world’s leading examples of publicly delivered universal healthcare. The NHS differs from most universal systems in that the government not only pays for care but employs the physicians and owns the hospitals — a fully nationalized model that goes further than what any US single-payer proposal contemplates.
The NHS’s problems in recent years are documented and severe. Long waits, staff shortages, deteriorating facilities, and declining public satisfaction have generated sustained political controversy. These problems are real.
They are also explained. The Health Foundation, a UK research organization, has calculated that if the NHS had received its historical average annual funding increase of 3.8% through the austerity years, it would have had £28 to £35 billion more per year by the early 2020s. Instead, Conservative governments deliberately held funding below that historical rate for more than a decade. The result was predictable: a system designed for one level of demand, underfunded to serve that demand, showed the stress.
The NHS did not fail because government cannot run healthcare. It degraded because a succession of governments made political choices to underfund it and then pointed to the degradation as evidence that the system itself was flawed. This distinction matters enormously for evaluating what the NHS experience tells us about universal healthcare. It is a lesson about the consequences of deliberate underfunding, not a lesson about the limits of public healthcare systems.
Model: Beveridge. Fully nationalized. Government employs physicians and owns hospitals.
What the Successful Systems Have in Common
The research on international healthcare systems identifies a consistent set of factors that appear in every well-functioning universal system, across all four models.
Adequate and sustained funding. Not just at launch, but maintained politically over decades. Every system that has degraded — the NHS under austerity, the VA under underfunding, Canada’s specialist capacity — did so because of deliberate decisions to limit spending. Every system that has performed well has been consistently and adequately funded.
Government negotiating power over prices. Taiwan, Germany, France, Japan, Australia — every system that controls costs does so through government negotiation of pharmaceutical and provider prices. The US government is currently prohibited by law from using this negotiating power in Medicare. The insulin price comparison — $98.70 in the US against $8.81 in comparable OECD countries on average — is the documented cost of that prohibition.
Low administrative overhead. Taiwan operates at 1.07% administrative overhead. The US multi-payer system consumes between a quarter and a third of all healthcare spending on administration. Single-payer or tightly regulated multi-payer systems achieve dramatically lower overhead through standardization.
Universal enrollment from day one. Systems that cover everyone from the start avoid the adverse selection problems that plague voluntary systems. When healthy people are required to participate, the risk pool is broad and stable. When they can opt out, the pool skews toward the sick and costs rise.
Sufficient provider capacity. Financing universal coverage without building enough physicians and facilities produces wait times. This is Canada’s lesson. Provider capacity must be built in parallel with coverage expansion.
Political insulation from insurance industry lobbying. This is the factor most specific to the American situation. Taiwan succeeded in 1995 in part because the private insurance industry was not powerful enough to prevent it. Germany built its system before a private insurance lobby existed. The US is attempting reform against an industry with $1.2 trillion in combined annual revenue and hundreds of millions in annual lobbying expenditure. No other country has attempted this transition under this level of organized opposition.
What the Struggling Systems Have in Common
The patterns of failure are equally consistent.
Systems that have struggled share one or more of the following: deliberate underfunding relative to demand; failure to build sufficient provider capacity alongside coverage expansion; incomplete universality through carve-outs and eligibility requirements that undermine both equity and efficiency; and, in some cases, inadequate price controls that allow costs to escalate despite universal coverage.
None of these failure modes are inherent to universal healthcare. They are political and policy failures that can be addressed through policy. The international evidence does not show a case of universal healthcare failing because government cannot administer healthcare. It shows cases of universal healthcare degrading because governments chose to underfund, underbuild, or underregulate it.
The Economic Case: Regulated Monopoly and Monopsony
Healthcare meets the economic criteria for a natural monopoly in ways that have been recognized by economists since the 19th century, when John Stuart Mill argued that natural monopolies should be regulated in the public interest rather than left to extract maximum profit from captive customers.
The criteria are specific. Demand is inelastic — you cannot choose not to need emergency care. Information is asymmetric — patients cannot evaluate the technical quality of care the way they can evaluate a consumer product. Provider markets are locally concentrated — most Americans have limited choice of hospitals and specialists. Insurance markets tend toward consolidation through adverse selection dynamics. And scale economies strongly favor single or tightly regulated payers — Taiwan’s 1.07% overhead versus the American quarter-to-a-third is the empirical demonstration of this.
The monopsony argument is equally important. A monopsony is a single buyer who can negotiate prices down, just as a monopolist can push prices up. Under single-payer, the government becomes the sole buyer in the healthcare market. This is how every other country controls drug and provider prices. It is why insulin costs $8.81 on average in comparable OECD countries and $98.70 in the United States. The US government is currently prohibited by law from exercising this power in Medicare. Every other government in the comparison exercises it routinely.
The decision to leave healthcare to unregulated markets — or to markets regulated primarily in the interest of insurers and pharmaceutical companies rather than patients — is not a neutral default. It is a policy choice with documented consequences.
The Empirical Summary
The evidence from international systems, examined as a whole, supports a set of conclusions that are consistent across the research literature.
Universal healthcare coverage is achievable in wealthy countries through multiple different mechanisms. Every wealthy country that has attempted it has succeeded. No wealthy country that has achieved it has abandoned it.
The United States spends nearly twice the per-capita amount of comparable countries and produces substantially worse population health outcomes on most measures. The performance gap is not explained by the health of the population at baseline or by the complexity of the US healthcare challenge — it is explained by the structure and incentives of the payment system.
Systems that perform well are adequately funded, exercise government negotiating power over prices, maintain low administrative overhead, cover everyone from the start, and have built sufficient provider capacity. Systems that struggle have failed on one or more of these dimensions, and in every case the failure is traceable to political choices rather than to inherent limits of public healthcare administration.
The US is not facing an unsolved problem. It is facing a solved problem that powerful financial interests have made politically difficult to implement.
Sources
Commonwealth Fund: Mirror Mirror 2024, international healthcare system performance.
Taiwan National Health Insurance Administration: NHI program statistics, administrative overhead data.
OECD Health Statistics 2024–2025: Per-capita spending, life expectancy, infant mortality, physician supply, hospital beds by country.
Commonwealth Fund International Health System Profiles: Germany, France, Japan, Australia, Canada, United Kingdom.
Canadian Institute for Health Information: Wait time data, physician and hospital capacity.
Health Foundation UK: NHS funding analysis, austerity impact on NHS resources.
RAND Corporation: Drug price international comparison, insulin pricing study.
Medicare Payment Advisory Commission: Medicare Advantage administrative data.
Physicians for a National Health Program: International model comparisons.
John Stuart Mill: Principles of Political Economy, natural monopoly framework.
Harvard health economics research: Adverse selection and insurance market consolidation.
KFF: US healthcare spending per capita, international comparison.
The Complete Single Payer Healthcare Series
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.